Abedul Haque
Overview
Explore the profile of Abedul Haque including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
George B, George S, Shi W, Haque A, Shi P, Eskandari G, et al.
J Hematol Oncol
. 2023 Jun;
16(1):61.
PMID: 37312210
No abstract available.
2.
Kaseb A, Haque A, Vishwamitra D, Hassan M, Xiao L, George B, et al.
Front Oncol
. 2022 Oct;
12:986305.
PMID: 36276070
Hepatocellular carcinoma (HCC) is an aggressive neoplasm with poor clinical outcome because most patients present at an advanced stage, at which point curative surgical options, such as tumor excision or...
3.
Haque A, Sahu V, Lombardo J, Xiao L, George B, Wolff R, et al.
J Hepatocell Carcinoma
. 2022 Aug;
9:823-837.
PMID: 35996397
Introduction: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancers. It is an aggressive neoplasm with dismal outcome because most of the patients present with an advanced-stage...
4.
George B, Haque A, Sahu V, Joldoshova A, Singh Y, Quinones J, et al.
Appl Immunohistochem Mol Morphol
. 2022 May;
30(5):333-339.
PMID: 35510772
The introduction of targeted therapy has revolutionized cancer treatment. Nonetheless, for this approach to succeed, it is crucial to identify the targets, particularly when activated, in tumor tissues. Phosphorylation is...
5.
Rashed-Al-Mahfuz M, Haque A, Azad A, Alyami S, Quinn J, Moni M
IEEE J Transl Eng Health Med
. 2021 May;
9:4900511.
PMID: 33948393
Objective: Chronic kidney disease (CKD) is a major public health concern worldwide. High costs of late-stage diagnosis and insufficient testing facilities can contribute to high morbidity and mortality rates in...
6.
Mohamed Y, Lee S, Xiao L, Hassan M, Qayyum A, Hiatia R, et al.
Oncotarget
. 2021 Apr;
12(8):756-766.
PMID: 33889299
Background: Sorafenib was the first systemic therapy approved for the treatment of Child-Turcotte-Pugh (CTP) class A patients with advanced hepatocellular carcinoma (HCC). However, there are no biomarkers to predict survival...
7.
Haque A, Brazeau D, Amin A
Eur J Cancer
. 2021 Apr;
149:165-183.
PMID: 33865202
Cancer is the second deadliest disease worldwide. Although recent advances applying precision treatments with targeted (molecular and immune) agents are promising, the histological and molecular heterogeneity of cancer cells and...
8.
Haque A, Rahman M, Fuchs J, Chen Z, Khuri F, Shin D, et al.
Cancer Lett
. 2020 Oct;
498:249-250.
PMID: 33092912
No abstract available.
9.
Abdel-Wahab R, Hassan M, George B, Carmagnani Pestana R, Xiao L, Lacin S, et al.
Oncology
. 2020 Oct;
98(12):836-846.
PMID: 33027788
Background: Liver reserve affects survival in hepatocellular carcinoma (HCC). Model for End-Stage Liver Disease (MELD) score is used to predict overall survival (OS) and to prioritize HCC patients on the...
10.
Morris J, Hassan M, Zohner Y, Wang Z, Xiao L, Rashid A, et al.
Hepatology
. 2020 Sep;
73(6):2278-2292.
PMID: 32931023
Background And Aims: Therapeutic, clinical trial entry and stratification decisions for hepatocellular carcinoma (HCC) are made based on prognostic assessments, using clinical staging systems based on small numbers of empirically...